4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.

Alto Neuroscience has commenced a Phase II clinical trial of histamine H3 receptor inverse agonist, ALTO-203, in treating patients with major depressive disorder (MDD). The double-blind ...